Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ingested (oral) alpha-MSH inhibits acute EAE.

Staley A Brod1, Zachary M Hood

  • 1Department of Neurology, University of Texas-Houston, Health Science Center, 6431 Fannin St, Houston, TX 77030, United States. staley.a.brod@uth.tmc.edu

Journal of Neuroimmunology
|November 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.

Journal of the neurological sciences·2023
Same author

The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

Autoimmunity reviews·2022
Same author

Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17 in the Central Nervous System in the Mouse Model of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

ImmunoHorizons·2022
Same author

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease.

Journal of Alzheimer's disease : JAD·2021
Same author

A proposal: How to study pro-myelinating proteins in MS.

Autoimmunity reviews·2021
Same author

Immune reconstitution therapy in NMOSD.

Multiple sclerosis and related disorders·2021
Same journal

Methodological concerns in the cutoff determination of a flow cytometric MOG-IgG assay: The need for independent validation.

Journal of neuroimmunology·2026
Same journal

Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

Journal of neuroimmunology·2026
Same journal

Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.

Journal of neuroimmunology·2026
Same journal

Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.

Journal of neuroimmunology·2026
Same journal

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same journal

Clinical characteristics of IgG4-related hypertrophic pachymeningitis with and without serum ANCA positivity.

Journal of neuroimmunology·2026
See all related articles

Oral administration of alpha-melanocyte-stimulating hormone (α-MSH) peptide effectively reduced inflammation and delayed disease onset in experimental autoimmune encephalomyelitis (EAE). This immunoactive protein shows potential for treating neuroinflammatory conditions.

Area of Science:

  • Neuroimmunology
  • Inflammation Research
  • Autoimmune Diseases

Background:

  • Experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis.
  • Oral administration of certain peptides, like type I IFN and SIRS, can inhibit EAE.
  • The immunoactive protein alpha-melanocyte-stimulating hormone (α-MSH) has anti-inflammatory properties.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of orally administered α-MSH peptide in a mouse model of EAE.
  • To determine if α-MSH can modulate immune responses and cytokine profiles in the central nervous system (CNS) and periphery.

Main Methods:

  • C57BL/6 (B6) mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55.
  • Mice were orally gavaged with either α-MSH peptide or control saline from 7 days before immunization until 14 days after.

Related Experiment Videos

  • Clinical disease progression, inflammatory foci in the CNS, and cytokine/chemokine levels (IL-2, IL12p70, SDF-1, MIP-1α, MIP-1γ) were analyzed.

    • Main Results:

    • Oral α-MSH peptide administration significantly delayed EAE onset and reduced inflammatory foci in the CNS.
    • CNS lymphocytes showed decreased levels of Th1-like encephalitogenic cytokines (IL-2, IL12p70) in the α-MSH group.
    • Peripheral SDF-1 levels increased, while CNS chemokines MIP-1α and MIP-1γ decreased in α-MSH treated mice compared to controls.

    Conclusions:

    • Ingested α-MSH peptide demonstrates significant anti-inflammatory effects in EAE.
    • Oral α-MSH inhibits CNS inflammation by reducing the migration of antigen-driven Th1 cells.
    • α-MSH peptide is a potential therapeutic agent for neuroinflammatory diseases.